Grant Heidrich joined Mayfield in 1982, bringing to the firm innate skill at anticipating emerging technology and market trends coupled with an ability to coalesce teams of people around a shared vision.
Grant currently serves on the Board of Directors for the following companies, including Cytokinetics, Dovebid, Millennium Pharmaceuticals (MLNM) and PolyFuel. All of these companies are Mayfield portfolio companies except GenPath.
He also lends his management savvy to the advisory board of Harvard-Partners Center for Genetics and Genomics, a non-profit partnership between Partners Healthcare and Harvard Medical School affiliated institutions.
Prior to joining Mayfield, Grant was a Vice President at Wood River Capital, a New York City-based venture capital firm. Grant also has served as President of the Western Association of Venture Capital and was a former board member of the National Venture Capital Association, where he served on the Regulatory and Government Affairs Committees.
Grant received his M.B.A. from Columbia University and his B.A. in Human Biology from Stanford University.